» Articles » PMID: 28732832

Current Approaches to the Management of Idiopathic Pulmonary Fibrosis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2017 Jul 23
PMID 28732832
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient care are to improve outcomes for patients by slowing the progression of the disease, extending life, and improving quality of life. A prompt, accurate diagnosis is important to enable patients to receive treatment early in the course of the disease and to be considered for lung transplantation. Two anti-fibrotic drugs, nintedanib and pirfenidone, have been shown to reduce decline in lung function in patients with IPF. In addition to pharmacological therapy, optimal management of IPF includes treatment of comorbidities, symptom relief, pulmonary rehabilitation, and palliative care. Patient education is important to enable patients to make decisions about their care and to help them manage their disease and the side-effects of anti-fibrotic drugs. Research continues into new treatments and combinations of treatments that may improve outcomes for patients with this devastating disease.

Citing Articles

Patient education for individuals with Interstitial Lung Disease: A scoping review.

Amin R, Vaishali K, Maiya G, Mohapatra A, Sinha M, Bhat A F1000Res. 2024; 13:405.

PMID: 38895701 PMC: 11184280. DOI: 10.12688/f1000research.147340.1.


Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.

Liu J, Wang F, Hong Y, Luo F Heliyon. 2024; 10(8):e29266.

PMID: 38655311 PMC: 11036012. DOI: 10.1016/j.heliyon.2024.e29266.


Patients with idiopathic pulmonary fibrosis and refractory cough have traction bronchiectasis and distorted airway architecture: a retrospective case review study.

Yamamura K, Hara J, Watanabe S, Kobayashi T, Kase K, Takeda Y J Thorac Dis. 2024; 16(3):2159-2166.

PMID: 38617783 PMC: 11009587. DOI: 10.21037/jtd-23-1443.


The Beneficial Impact of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: A Review of the Current Literature.

Sanduzzi Zamparelli S, Lombardi C, Candia C, Iovine P, Rea G, Vitacca M J Clin Med. 2024; 13(7).

PMID: 38610791 PMC: 11012394. DOI: 10.3390/jcm13072026.


The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks.

Wang H, Tsai S, Lin Y, Hou J, Chao C BMC Pulm Med. 2024; 24(1):160.

PMID: 38566026 PMC: 10986056. DOI: 10.1186/s12890-024-02947-5.